SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ArQule -- Ignore unavailable to you. Want to Upgrade?

To: JZGalt who wrote (127)12/19/1997 1:21:00 PM
From: SteveG  Respond to of 399
 
<I'm not down on ARQL, but I own more of ABSC...>

I agree that ABSC is a company to watch (see my email to you for recent H&Q ABSC report). I understand that Rachel's pick going into their *conference* is ARQL, fwiw-

Regards-

Steve



To: JZGalt who wrote (127)12/19/1997 1:32:00 PM
From: Mike Winn  Read Replies (1) | Respond to of 399
 
Hi Dave,

I take a look at ABSC, it has a market cap of 245M while ARQL has a market cap of 222M. ARQL has sales of $14.1M while ABSC has sales of $0.7M. ARQL can potentially get huge revenue if one of its collaboration turns into a big commercial product. I think I make up my mind that ARQL has more value than ABSC.

Thanks for bringing up ABSC.

Mike.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News